第 1 到 29 筆結果,共 29 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2022 | Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy | TA-CHEN HUANG ; Liang C.-W.; Li Y.-I.; GUO, JHE-CYUAN ; CHIA-CHI LIN ; Chen Y.-J.; ANN-LII CHENG ; CHIH-HUNG HSU | Journal of Cancer Research and Clinical Oncology | 2 | 2 | |
2 | 2022 | B Cells in Tumor Microenvironment Associated With The Clinical Benefit to Programmed Cell Death Protein-1 Blockade Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma | JHE-CYUAN GUO ; Hsu, Chia-Lang; YEN-LIN HUANG ; CHIA-CHI LIN ; TA-CHEN HUANG ; Wu, I-Chen; Lin, Chen-Yuan; Lien, Ming-Yu; HUNG-YANG KUO ; ANN-LII CHENG ; CHIH-HUNG HSU | Frontiers in oncology | 2 | 1 | |
3 | 2022 | Deleterious alterations of DNA damage response and repair genes and clinical benefit to anti-PD-1 therapy in esophageal squamous cell carcinoma | JHE-CYUAN GUO ; CHIA-CHI LIN ; Hsu, Chia-Lang; TA-CHEN HUANG ; HUNG-YANG KUO ; Lin, Chen-Yuan; Lien, Ming-Yu; ANN-LII CHENG ; CHIH-HUNG HSU | Esophagus : official journal of the Japan Esophageal Society | 0 | 0 | |
4 | 2020 | Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours | de Bono J.; CHIA-CHI LIN ; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; JIH-HSIANG LEE ; CHIH-HUNG HSU ; CHIH-HSIN YANG ; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; ANN-LII CHENG | British Journal of Cancer | 19 | 17 | |
5 | 2020 | A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors | JIH-HSIANG LEE ; WEI-WU CHEN ; CHIH-HUNG HSU ; Yen Y.-H.; CHIH-HSIN YANG ; ANN-LII CHENG ; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; CHIA-CHI LIN | Investigational New Drugs | 39 | 36 | |
6 | 2019 | Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors | Doi T.; CHIH-HSIN YANG ; Shitara K.; Naito Y.; ANN-LII CHENG ; Sarashina A.; Pronk L.C.; Takeuchi Y.; CHIA-CHI LIN | Targeted Oncology | 21 | 14 | |
7 | 2019 | Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma | Ta-Chen Huang ; CHIA-CHI LIN ; Wu Y.-C.; CHIA-HSIEN CHENG ; JANG-MING LEE ; HSIU-PO WANG ; PEI-MING HUANG ; Feng-Ming Hsu ; KUN-HUEI YEH ; ANN-LII CHENG ; KAI-YUAN TZEN ; CHIH-HUNG HSU | Journal of the Formosan Medical Association | 8 | 6 | |
8 | 2018 | A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma | SHIH-HUNG YANG ; YU-YUN SHAO ; CHIA-CHI LIN ; SUNG-HSIN KUO ; ANN-LII CHENG ; KUN-HUEI YEH | Anticancer Research | 3 | 2 | |
9 | 2017 | A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement | YUN CHIANG ; CHIA-HSIEN CHENG ; CHAO-YUAN HUANG ; YU-CHIEH TSAI ; Chia-Chi Lin ; CHIH-HUNG HSU ; ANN-LII CHENG ; YEONG-SHIAU PU | Journal of the Formosan Medical Association | 7 | 6 | |
10 | 2015 | Postchemoradiotherapy pathologic stage classified by the American joint committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinoma | JHE-CYUAN GUO ; Ta-Chen Huang ; CHIA-CHI LIN ; MIN-SHU HSIEH ; Chang C.-H.; PEI-MING HUANG ; JANG-MING LEE ; Feng-Ming Hsu ; CHIA-HSIEN CHENG ; HSIU-PO WANG ; KUN-HUEI YEH ; ANN-LII CHENG ; CHIH-HUNG HSU | Journal of Thoracic Oncology | 15 | 16 | |
11 | 2014 | A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors | Ghamande S.; CHIA-CHI LIN ; Cho D.C.; Shapiro G.I.; Kwak E.L.; Silverman M.H.; Tseng Y.; Kuo M.-W.; Mach W.B.; Hsu S.-C.; Coleman T.; CHIH-HSIN YANG ; ANN-LII CHENG ; Ghalib M.H.; Chuadhary I.; Goel S. | Investigational New Drugs | 23 | 15 | |
12 | 2014 | A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies | CHIA-CHI LIN ; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU ; Su W.-P.; KUN-HUEI YEH ; YEN-SHEN LU ; ANN-LII CHENG ; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; CHIH-HSIN YANG | British Journal of Cancer | 62 | 64 | |
13 | 2013 | Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy | WEI-WU CHEN ; CHIA-CHI LIN ; TA-CHEN HUANG ; ANN-LII CHENG ; KUN-HUEI YEH ; CHIH-HUNG HSU | Anticancer Research | 11 | 11 | |
14 | 2009 | Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHIA-HSIEN CHENG ; CHAO-YUAN HUANG ; YU-CHIEH TSAI ; Feng-Ming Hsu ; KUO-HOW HUANG ; ANN-LII CHENG ; YEONG-SHIAU PU | International Journal of Radiation Oncology Biology Physics | 27 | 22 | |
15 | 2009 | National Center of Excellence for Clinical Trials and Research at National Taiwan University Hospital | CHIA-CHI LIN ; CHIH-HSIN YANG ; ANN-LII CHENG ; Chan W.-K.; HONG-NERNG HO | Drug Information Journal | 3 | 2 | |
16 | 2008 | Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment | ZHONG-ZHE LIN ; CHIUN HSU ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HUNG HSU ; CHIA-CHI LIN ; ANN-LII CHENG ; PAN-CHYR YANG ; CHIH-HSIN YANG | Lung Cancer | 5 | 1 | |
17 | 2008 | Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma | CHIA-CHI LIN ; YEONG-SHIAU PU ; CHIH-HUNG HSU ; Keng H.-Y.; ANN-LII CHENG ; CHIH-HSIN YANG | Urologic Oncology: Seminars and Original Investigations | 8 | 7 | |
18 | 2008 | Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial | CHIUN HSU ; SUNG-HSIN KUO ; Hu F.-C.; ANN-LII CHENG ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIA-CHI LIN ; Huang T.-C.; PAN-CHYR YANG ; CHIH-HSIN YANG | Lung Cancer | 14 | 11 | |
19 | 2007 | Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHIA-HSIEN CHENG ; HSIU-PO WANG ; JANG-MING LEE ; KUN-HUEI YEH ; CHIH-HSIN YANG ; Lin J.-T.; ANN-LII CHENG ; Lee Y.-C. | Annals of Oncology | 39 | 36 | |
20 | 2007 | Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma | CHIA-CHI LIN ; KUN-HUEI YEH ; CHIH-HSIN YANG ; CHIUN HSU ; YU-CHIEH TSAI ; Hsu W.-L.; ANN-LII CHENG ; CHIH-HUNG HSU | Anti-Cancer Drugs | 10 | 8 | |
21 | 2007 | Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial | CHIA-CHI LIN ; CHIH-HUNG HSU ; Hour T.-C.; ANN-LII CHENG ; CHAO-YUAN HUANG ; KUO-HOW HUANG ; Chen J.; YEONG-SHIAU PU | Urologic Oncology: Seminars and Original Investigations | 6 | 6 | |
22 | 2007 | Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHAO-YUAN HUANG ; Keng H.-Y.; YU-CHIEH TSAI ; KUO-HOW HUANG ; ANN-LII CHENG ; YEONG-SHIAU PU | Anti-Cancer Drugs | 32 | 29 | |
23 | 2007 | Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHAO-YUAN HUANG ; YU-CHIEH TSAI ; KUO-HOW HUANG ; ANN-LII CHENG ; YEONG-SHIAU PU | Urology | 24 | 21 | |
24 | 2007 | Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHAO-YUAN HUANG ; ANN-LII CHENG ; Vogelzang N.J.; YEONG-SHIAU PU | Journal of Urology | 20 | 18 | |
25 | 2007 | A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer | CHIA-CHI LIN ; ANN-LII CHENG ; CHIH-HUNG HSU ; YEN-SHEN LU ; CHIUN HSU ; KUN-HUEI YEH ; Wu C.-Y.; CHIUN-SHENG HUANG ; CHIH-HSIN YANG | Anticancer Research | 2 | 2 | |
26 | 2007 | Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial | CHIA-CHI LIN ; CHIUN HSU ; CHIH-HUNG HSU ; Hsu W.-L.; ANN-LII CHENG ; CHIH-HSIN YANG | Investigational New Drugs | 105 | 103 | |
27 | 2006 | Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: An effective regimen with low toxicity | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHAO-YUAN HUANG ; ANN-LII CHENG ; Chen J.; Vogelzang N.J.; YEONG-SHIAU PU | Cancer | 24 | 24 | |
28 | 2002 | A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil | CHIH-HUNG HSU ; ANN-LII CHENG ; CHIUN HSU ; CHIH-HSIN YANG ; YEN-SHEN LU ; CHIA-CHI LIN ; Bu C.-F.; KUN-HUEI YEH | Anticancer Research | 12 | 12 | |
29 | 2001 | A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer | CHIA-CHI LIN ; CHIH-HUNG HSU ; Chen J.; Tsai T.-C.; ANN-LII CHENG ; YEONG-SHIAU PU | Anticancer Research | 14 | 13 |